Results
eNauka >
Results >
High Doses Of Imatinib Mesylate (800mg/Day) Significantly Improve Rates Of Major And Complete Cytogenetic Remissions (Mcr, Ccr) - Results From The First Planned Interim Analysis Of A Multicenter, Randomised, 2-Arm - Phase Iii Study Comparing Imatinib Stan
| Title: | High Doses Of Imatinib Mesylate (800mg/Day) Significantly Improve Rates Of Major And Complete Cytogenetic Remissions (Mcr, Ccr) - Results From The First Planned Interim Analysis Of A Multicenter, Randomised, 2-Arm - Phase Iii Study Comparing Imatinib Stan | Authors: | Andreas, AP; Boskovic, Darinka V; Gastl, Guenther A | Issue Date: | 2008 | Publication: | HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | ISSN: | 0390-6078 Haematologica Search Idenfier |
Type: | Conference Paper | Collation: | vol. 93 str. 0406 | WoS-ID: | 000263430200407 | URI: | https://enauka.gov.rs/handle/123456789/814942 | Metadata source: | (Preuzeto iz Nasi u WoS) | M-category: | Mp. category will be shown later |
3
WEB OF SCIENCETM
Google ScholarTM
Items in eNauka are protected by copyright, with all rights reserved, unless otherwise indicated.